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ABSTRACT A mechanism of signal transduction by human choriogonadotropin (hCG) has been proposed. Competitive
inhibition of the binding of hCG to its receptor by the serine protease inhibitors led to the identification of local structural
homology of an extracellular region of the receptor with the reactive site loop of chymotrypsin inhibitor. Synthetic peptides
from the extracellular domain of luteinizing hormone-choriogonadotropin (LH/CG) receptor, rationally designed on the basis
of this homology, were found to affect hormone-receptor binding and bioactivity. A receptor peptide incorporating one
complete structural unit of the leucine-rich repeats motif of the extracellular domain of the receptor significantly increased
hCG-receptor binding in a dose-dependent manner. However, the testosterone production in a Leydig cell bioassay was
inhibited in the presence of this peptide. The agonistic effect on the hCG-receptor binding and the antagonistic effect on the
testosterone production of a receptor peptide suggests the possibility of more than one quasi-equivalent receptor-binding
site on the hormone. Hormone-induced receptor oligomerization may therefore be involved in the mechanism of signal
transduction by hCG.
INTRODUCTION
The recognition and binding of ligands such as hormones
and growth factors to specific cell surface receptors are the
prerequisites for their functions. Interaction of luteinizing
hormone (LH) and choriogonadotropin (CG) with the
LH/CG receptor on gonadal target cells is the first step in
the cascade of events associated with their endocrine ac-
tions. This interaction triggers a signal, mediated by mem-
brane-associated intracellular G-proteins (Gilman, 1984),
leading to the increase in adenylyl cyclase activity and
followed by the corresponding increase in cAMP concen-
tration. The increase in cAMP levels eventually results in
the synthesis and secretion of steroid hormones (Dufau et
al., 1980). A large number of other ligands like neurotrans-
mitters and neuromodulators, in addition to gonadotropins,
bring about changes in the cellular metabolism by interac-
tion with receptors that are coupled to intracellular effector
enzymes via G-proteins. In recent years, significant under-
standing of the means by which ligands trigger the cellular
responses has been achieved at the structural level (Young,
1992; Sprang and Bazan, 1993).
The crystallographic structure of hCG has been deter-
mined at high resolution by two independent groups
(Lapthorn et al., 1994; Wu et al., 1994). The crystal struc-
ture of placental ribonuclease inhibitor, a member of the
leucine-rich repeats family of proteins to which LU/CG
receptor belongs, has also been determined (Kobe and De-
isenhofer, 1993). Subsequently, a knowledge-based model
of the homologous domain of the gonadotropin receptors
(Kajava et al., 1995) has been proposed. These high-reso-
lution structural analyses have triggered interest in explor-
ing the mechanism by which the information is transmitted
into the cell upon binding of hCG to the membrane-associ-
ated LH/CG receptor. Several independent models for hCG-
receptor recognition have been proposed (Moyle et al.,
1995; Jiang et al., 1995; Grewal et al., 1994). However,
these models do not exhibit any mutual agreement. We have
experimentally analyzed the hCG-receptor binding by using
designed synthetic peptides from the extracellular domain
of the LH/CG receptor. These studies shed light on the
possible mechanism of signal transduction by hCG.
EXPERIMENTAL PROCEDURES
Materials
All of the chemicals, including the Fmoc amino acid derivatives, were
obtained from Nova Biochem (Laufelfingen, Switzerland). The solvents/
reagents for cleavage were procured either from Sigma Chemical Co. (St.
Louis, MO) or from Fluka Chemie AG (Buchs, Switzerland). The high-
performance liquid chromatography-grade acetonitrile and other solvents
for purification were obtained from SD Fine Chemical (Bombay, India).
hCG with a biological activity of 11,370 IU/mg was procured from IBSA
(Lugano, Switzerland). 1251 and 1,3,4,6-tetrachloro-3a,6a-diphenylgly-
couril (lodo-Gen) was purchased from Amersham International (Bucking-
hamshire, England). Aprotinin, Tris(hydroxymethyl) aminomethane (Tris),
sodium azide, and bovine serum albumin (BSA) were procured from Sigma
Chemical Co. or Boehringer Mannheim (Mannheim, Germany). The re-
agents for buffer preparations were procured from E. Merck (Bombay,
India).
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Peptide synthesis
The peptide synthesis was carried out by solid-phase methodology, apply-
ing the standard Fmoc chemistry by LKB Biolynx 4175 semiautomatic
synthesizer on Novasyn KA resin. The peptides were cleaved from the
resin, and the crude peptides were then purified by reverse-phase high-
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performance liquid chromatography (Waters Prep LC3000 System) on a
preparative Waters Deltapak C18-100 A column, using a TFA/acetonitrile
solvent system. The purity was confirmed by N-terminal sequencing on a
Applied Biosystems protein sequencer (model 470A).
Radio-receptor assay
The peptides were evaluated for their effect on the binding of radiolabeled
human choriogonadotropin (['25I]hCG) with particulate Leydig cell
LH/CG receptor by radio-receptor assay. The hCG was labeled with [1251]
by the Iodo-Gen method (Fraker and Speck, 1978). Testes of adult Wistar
rats were used as the source of plasma membranes, prepared by the method
of Dighe and Moudgal (1983). The receptor-enriched membrane fractions
were incubated for 2 h at 37°C with varying dilutions of either the peptides
or the aprotinin in the presence of ['25I]hCG (100,000 cpm). The radioac-
tivity in the pelleted complexes of the hormone-receptor was counted in a
LKB 1260 MultiGamma II Gamma counter. The maximum binding
(100%) corresponds to the binding of ['25I]hCG to the receptors in the
absence of cold hCG or any other ligand.
Leydig cell bioassay
The dose-dependent effect of the 38-mer peptide on the hCG activity was
estimated using mouse Leydig cell preparation in vitro (Van Damme et al.,
1974). Leydig cells produce testosterone upon stimulation with LH or
hCG. In brief, semipurified preparations of mouse Leydig cells were
stimulated with various doses of hCG in the range of 3.9-1000 pg/ml. The
concentration corresponding to the midportion of the standard curve (125
pg/ml) was used for stimulation of testosterone production by Leydig cells
in the presence of the peptide. For the assay, varying concentrations of the
38-mer peptide were added in duplicate to assess its effect on testosterone
stimulation by a constant amount of hCG (125 pg/ml). Tubes containing
cells and hCG alone served as the 100% stimulation in the absence of the
peptide. The testosterone produced was assayed by radioimmunoassay with
a kit provided by World Health Organization. Bioneutralizing capacity of
the peptide was estimated by its inhibition of testosterone production.
Computer modeling
The ALIGN program (available with a NBRF sequence data package on
,VAXII) was used for sequence comparisons (Dayhoff et al., 1983). The
BIOSYM molecular modeling software INSIGHTII (Biosym Technolo-
gies) was used on a INDIGO2 workstation (Silicon Graphics) for all aspects
of model building, analysis, and display of structural data. Knowledge-
based modeling of the receptor was carried out with the HOMOLOGY
module based on the TSH receptor coordinates (Kajava et al., 1995). The
model was refined in an AMBER force field (Weiner et al., 1986) using
energy minimization. A distance-dependent dielectric constant of 4 was
used, and no cross-term energies were included. The DOCKING module in
BIOSYM was used to build the model of the hCG-receptor complex.
RESULTS AND DISCUSSION
Structural relationship between LH/CG receptor
and serine protease inhibitors
The proteinaceous inhibitors of serine proteases inhibit the
binding of gonadotropins to their receptors. lodinated hCG
has been shown to be displaced in a dose-dependent manner
from the plasma membrane preparations of rat ovaries by
aprotinin (Wilks and Hui, 1987). Aprotinin is a single
polypeptide chain of 58 amino acids with inhibitory speci-
ficities for serine proteases like trypsin and chymotrypsin.
The dose-dependent inhibition of radiolabeled FSH binding
to the soluble receptor as well as receptor-enriched mem-
brane fractions by aprotinin has also been shown (Grasso
and Reichert, 1989). The serine protease inhibitors were
earlier reported to block hormonal activation of adenylate
cyclase (Richert and Ryan, 1977) in a variety of tissues. The
antagonistic effect of the proteinaceous inhibitors of serine
proteases on hCG-receptor binding could have structural
implications. Therefore, radioreceptor assays were carried
out in the presence of varying concentrations of aprotinin,
and it was confirmed that aprotinin competitively inhibits
hCG-receptor binding in the millimolar concentration range
(Fig. 1). The curve shows binding of [1251]hCG in the
presence of various concentrations of aprotinin. The bound
[125I]hCG was -62% with respect to the control at the
aprotinin concentration of 0.1 mM. When the concentration
was increased to 1.5 mM, the hormone binding decreased to
-18%. For comparison, the displacement of [125I]hCG by
cold hCG, which takes place in the micromolar concentra-
tion range, is also shown.
The antagonistic effect of a serine protease inhibitor in
hCG-receptor binding could imply that the inhibitor binds to
the receptor-binding site of the hormone or to the hormone-
binding site of the receptor, thereby causing steric inhibi-
tion. Because aprotinin interferes primarily in the recogni-
tive process, it may mimic the functional determinants of
either the hormone or the receptor. It has been suggested
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FIGURE 1 Competitive inhibition of [125I]hCG binding to LH/CG re-
ceptor-enriched rat luteal membranes by increasing concentrations of cold
hCG and aprotinin.
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functional determinant of hCG (Willey and Leidenberger,
1989). Therefore it was expected that the reactive site of
inhibitors of chymotrypsin may have analogy with the hor-
mone-binding site of the LHICG receptor. This receptor,
like other G-protein-coupled receptors, is organized into
distinct structural domains for hormone binding and effector
functions. The hormone binds primarily in the extracellular
domain of the receptor (Xie et al., 1990; Moyle et al., 1991).
The reactive site of serine protease inhibitors is made up of
an exposed loop of a characteristic conformation (Las-
kowski and Kato, 1980). The crystal structures of a large
number of different proteinaceous inhibitors of serine pro-
teases have been deposited in the Brookhaven Protein Data
Bank (Bernstein et al., 1977). Although the inhibitors are
unrelated in terms of the sequence and the overall structures,
the reactive sites show significant structural similarity,
which correlates with the overlapping specificity of these
inhibitors.
The sequence alignment between the LH/CG receptors
from various species and the inhibitors of serine proteases
led to the identification of two stretches from the receptor
sequence (Grewal et al., 1994), one long and one short, with
one continuous stretch of chymotrypsin inhibitor-2 (CI-2).
The porcine receptor sequences from 137 to 167 and from
99 to 104 match well with the CI-2 sequence from 46 to 83.
The corresponding regions of the receptors from the rest of
the species also show significant homology, as the receptors
themselves are highly homologous. The alignment of
LH/CG receptor sequences from the four species with the
reactive site stretches of CI-2 and the closely related eglin C
is shown in Fig. 2 A. There are -50% chemically similar
residues between CI-2 and the receptor stretches.
The model of the leucine-rich region of the extracellular
domain of the LH/CG receptor (Fig. 2 B) was based on the
leucine-rich repeats pattern-matching with placental ribonu-
clease inhibitor crystal structure (Kobe and Deisenhofer,
1993), and was obtained (see Experimental Procedure) by
transcribing the homologous thyrotropin receptor model
(Kajava et al., 1995) to the LH/CG receptor sequence. The
comparison of the backbone conformation (McPhalen and
James, 1987) of the reactive site loop of CI-2 (Fig. 2 C) and
the corresponding segment of the LH/CG receptor model
shows remarkable correspondence. Although the overall
structures of these two independent proteins are very dif-
ferent, there is obvious local similarity between the two
proteins in the homologous sequence segments (Fig. 2 A).
Thus the reactive site loop of the serine protease inhibitors
may actually be a fortuitous mimic of a small portion of the
LH/CG receptor.
Designed peptides affect receptor binding and
testosterone production by hCG
The similarity of the reactive site loop of CI-2 to a receptor
segment implies that the synthetic peptides from this region
hCG-receptor binding. A total of four peptides were de-
signed. The relative positions of these peptides with respect
to the receptor sequence are shown in Fig. 3 A. The longest
peptide (38-mer) consists of two independent receptor
stretches, Leu'37-Val167 and Asn99-Lys'04, which are
joined via an alanine residue to maintain spatial juxtaposi-
tion. The other peptides were 25 (25-mer), 24 (24-mer), and
16 (16-mer) residues long. The 25-mer (Pro143-Val167) in-
cludes residues corresponding to the core loop of the inhib-
itor. The 24-mer (Ile140-Gly'63) and 16-mer (Lys158-Val167
and Asn99-Leu103) predominantly correspond to the N-
terminal and the C-terminal parts of the 38-mer peptide. In
addition, an entirely unrelated 33-residue peptide of a length
comparable to that of the receptor peptides was also used as
a negative control (Fig. 3 B).
The effects of these peptides on the binding of hCG to its
receptor were studied by radio-receptor assay (Fig. 3 C).
The 38-mer showed a significant dose-dependent increase
in the binding of radiolabeled hCG to the receptor, reaching
150% at 1 mM concentration. The 25-mer that structurally
corresponds to the core loop also exhibited enhanced
[125I]hCG binding to the receptor, although this was slightly
lower, reaching 126% at this concentration. However, the
peptides covering the N-terminal (24-mer) and the C-termi-
nal (16-mer) regions of the 38-mer showed no effect on
hCG-receptor binding. No change in binding was observed
with the nonspecific peptides as well. The structural rela-
tionship with the serine protease inhibitor was used as the
receptor peptides were designed. Therefore, as in the case of
aprotinin, a decrease in the hCG-receptor binding was ex-
pected in the presence of these peptides. Yet the observed
dose-dependent increase still suggests a role for this recep-
tor loop in hormone-receptor recognition.
The 38-mer receptor peptide, however, does not exhibit
any dose-dependent enhancement of testosterone produc-
tion in the Leydig cell bioassay. On the contrary, an inverse
effect was observed. The assay was performed in the pres-
ence of different peptide concentrations. The hCG concen-
tration used in this assay corresponds to the midpoint of the
dose-response curve of hCG-induced testosterone produc-
tion by mouse Leydig cells (Fig. 4 A). In hCG-stimulated
Leydig cells, increasing concentration of 38-mer peptide
resulted in a proportional inhibition of testosterone produc-
tion (Fig. 4 B). The testosterone production remained neg-
ligible up to the peptide concentration of 0.5 mM. However,
with a further increase in the concentration of the peptide
there was a dose-dependent inhibition of testosterone pro-
duction leading to more than 80% inhibition at a peptide
concentration of 1.5 mM. The 24-mer and the nonspecific
peptide do not show any dose-dependent effect on the
testosterone production.
Thus the Leydig cell bioassay and the radio-receptor
assay, involving a synthetic peptide designed on the basis of
structural analogy with the proteinaceous serine protease
inhibitors, suggest that the receptor segments corresponding
to this peptide have a role in hCG recognition. The receptor
peptide (38-mer) showed dose-dependent inhibition of hCG
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FIGURE 2 (A) Sequence alignment of the reactive site segments of the serine protease inhibitors with the extracellular domains of the human (hLHR),
porcine (pLHR), mouse (mLHR), and rat (rLHR) LH/CG receptors. The serine protease inhibitors are chymotrypsin inhibitor (CI-2) and eglin C (EGLC).
The alignment of the equivalent residues is highlighted. The numbering corresponds to porcine receptor (top) and CI-2 (bottom) sequences. (B) A stereo
diagram showing the model of the leucine-rich domain of the LH/CG receptor. (C) A stereo diagram showing the superimposition of the backbone
conformations of the reactive site loop of CI-2 and the LH/CG receptor segment that showed sequence similarity with CI-2.
bioactivity. However, the radio-receptor assay in the pres-
ence of this peptide showed enhanced binding ofhCG to the
particulate LH/CG receptor in a dose-dependent manner.
On the other hand, aprotinin neutralizes the bioactivity of
hCG as well as competitively inhibiting hCG-receptor bind-
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FIGURE 3 (A) The sequences and
the relative positions of the four pep-
tides corresponding to the porcine
LH1CG receptor designed for the re-
ceptor binding and bioneutralizing
activity assays. (B) The sequence of a
33-residue nonspecific peptide used
as a negative control for receptor
binding and bioneutralizing activity
assays. <E represents pyroglutamic
acid. (C) Percentage binding of
['251]hCG to the particulate rat Ley-
dig cell membrane preparations in the
presence of varying concentrations of
the four receptor peptides and the
nonspecific peptides.



















The unexpected behavior of the LH/CG receptor peptides in
terms of the receptor binding and testosterone production by
hCG can be interpreted if the signaling mechanism of hCG
involves ligand-induced receptor oligomerization. The li-
gand-induced receptor oligomerization has been recognized
to be a key event in signal transduction by many membrane-
bound receptors (Heldin, 1995; Yarden and Schlessinger,
1987; Elberg et al., 1990; Yarden and Ullrich, 1988). De-
pending on the receptor and the subunit nature of the ligand,
homomeric as well as heteromeric association-forming oli-
gomers of different stoichiometric compositions have been
observed (Young, 1992). The first structural evidence sup-
porting this phenomenon was provided by the crystal struc-
ture of growth hormone complexed with its receptor (de
Vos et al., 1992). The structure reveals that one molecule of
the growth hormone binds to two identical molecules of the
receptor, each recognizing a different portion of the hor-
















FIGURE 4 (A) Dose-response curve of hCG-stimulated testosterone production. The actual amounts of the testosterone produced by Leydig cells upon
stimulation with various doses of hCG are plotted. (B) Testosterone production by mouse Leydig cells in the presence of hCG (200 ,ul of 125 pg/ml) and
increasing concentration of the three peptides, namely, 38-mer, 24-mer, and the nonspecific peptide. One hundred microliters of various peptide
concentrations were added to each tube containing Leydig cells and hCG. The incubation of this mixture was carried out at 37°C for 3 h. One hundred
percent on the y axis represents testosterone produced by Leydig cells in the absence of any peptide.
receptor is sequential, with the two sites having different
binding affinities. The crystal structure of tumor necrosis
factor-soluble receptor complex (Banner et al., 1993) de-
picts ligand-dependent aggregation induced by a trimeric
ligand. In a symmetrically organized structure of the com-
plex, each of the three bound receptor molecules binds at the
site created by the interface of two subunits. The enhanced
binding but depleted receptor activation by hCG in the
presence of the designed peptide can be explained, if such a
mechanism of receptor activation by hCG is hypothesized.
In this case, the quasiequivalent multiple binding sites on
the ligand may result in receptor association bringing neigh-
boring receptor molecules in the membrane bilayer into
close proximity and the generation of new intracellular sites
for effector functions.
The receptor peptides, which enhance binding of hCG to
its receptor at millimolar concentrations, could bind to the
hormone while simultaneously allowing the binding of a
receptor molecule on an independent site. In a radio-recep-
tor assay in which a [125I]hCG is pelleted out with the
Leydig cell membrane preparations containing LH/CG re-
ceptors, reduction in the stoichiometry of the ligand-recep-
tor binding would lead to an increase in the radiolabeled
hormone available for binding to the receptor on the mem-
brane. In these circumstances, an increase in the bound
[125I]hCG with increasing concentrations of the peptide can
be anticipated. However, not completing the stoichiometry
of the ligand-receptor complex would imply that the cyto-
solic sites for effector functions may not be generated,
leading to the abortion of the signal transduction cascade.
Thus enhancement in ['25I]hCG binding to the receptor
should not be accompanied by testosterone production,
which should actually decrease as a function of the increas-
ing concentration of the peptide, if the mechanism of signal
transduction by hCG is achieved by ligand-induced oli-
gomerization. The observed reduction in the testosterone
production (Fig. 4 B) with respect to the increase in the
concentration of 38-mer precisely follows this logic.
The hCG molecule is a heterodimer made up of two
nonidentical polypeptide chains. However, the two subunits
are topologically equivalent and are related by a pseudo-
twofold symmetry (Lapthom et al., 1994; Wu et al., 1994).
In addition, both of the subunits of the hormone adopt a
cystine-knot topology (McDonald and Hendrickson, 1993)
common to the growth factors like nerve growth factor
(NGF) (McDonald et al., 1991)), tissue growth factor (TGF)
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13 (Daopin et al., 1992), and platelet-derived growth factor
(PDGF) B (Oefner et al., 1992). These growth factors are
known to be homodimers and have been shown to induce
receptor dimerization upon binding. Besides the topological
similarities to the growth factors, hCG has also been sug-
gested to have growth-factor-like functional characteristics
(Lazar et al., 1995; Yoshimura et al., 1994). It is therefore
possible to conceive of two quasiequivalent binding sites on
the hormone, considering the substantially asymmetrical
nature of the hCG dimer, as has been observed in the case
of growth hormone (de Vos et al., 1992). Consequently, the
effective number of available membrane-associated recep-
tor molecules for the radiolabeled ligand increases. The
binding of peptides to the radiolabeled hCG facilitates sub-
sequent binding of the hormone to the receptor, but prevents
oligomerization, henceforth resulting in an enhanced radio-
activity in the assay. On the other hand, a comparatively
large and substantially different molecule like aprotinin,
even while partially sharing topology with the receptor
peptide, could sterically prevent the hormone-induced re-
ceptor association. In the absence of any other ligand, the
receptor alone will saturate the binding sites of the hormone.
A model of the complex of LH/CG receptor and hCG,
consistent with the hCG-induced receptor dimerization, was
constructed in light of the above data and the knowledge of
the three-dimensional structures of hCG (Lapthorn et al.,
1994; Wu et al., 1994) and the gonadotropin receptors
(Kajava et al., 1995). The approximate dimer symmetry and
the experimental knowledge of the segments of hCG (Ryan
et al., 1987; Charlesworth et al., 1987; Reed et al., 1991;
Merz and Dorner, 1985) and the receptor (Roche et al.,
1992; present study) involved in the binding were utilized in
this model building. A receptor molecule was first docked
with the hormone by using the binding site segments as
guide, and the docking was optimized by monitoring the
energy of interaction. The approximate twofold symmetry
of hCG was used for generating the second receptor mole-
cule from the first, which was then independently optimized
again by evaluating the interaction energy. The final model
of the hormone receptor complex is shown in Fig. 5. In this
model, two binding sites of hCG are occupied by two
independent receptor molecules. The region of the receptor
modeled here corresponds only to the leucine-rich repeat
region of the extracellular domain. The unmodeled regions
of the receptor are schematically shown as blobs. Fig. 5 also
indicates the juxtaposition of the hCG-receptor complex
with respect to the membrane. As shown in the model, the
two receptor molecules may interact with themselves
through the transmembrane domains and the adjacent,
small, non-leucine-rich regions of the extracellular domains.
This would facilitate bringing together the cytosolic do-
mains and the creation of an intracellular site for effector
functions. Almost all of the repeats in the receptor model are
involved in hCG binding (Fig. 5), and the segment corre-
sponding to 38-mer covers only one of them. Thus the
peptide (which is indicated in the figure by grey ribbon)
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FIGURE 5 A model illustrating dimerization of the LH/CG receptor by
a single hCG molecule. H, RI, and R2 correspond to the hormone and the
two receptor molecules, respectively. The hormone (orange) and the
leucine-rich region of the LH/CG receptor (blue) are shown as ribbons. The
N- and C-terminal regions of the extracellular (light yellow), transmem-
brane (yellow), and cytosolic (light yellow) domains that do not have a
leucine-rich motif are shown schematically as blobs. The 38-mer peptide is
highlighted by grey ribbon in both of the receptor molecules.
incorporates only a fraction of the hormone-binding site.
This explains the comparatively low affinity of the peptide.
Certain ligand-dependent observations have also been
made regarding the mechanism of signal transduction in-
volving LH/CG and other similar receptors that lend indi-
rect support to the receptor dimerization model. The hCG-
induced aggregation of receptor molecules on the cell
surface was reported several years ago (Podesta et al., 1983,
1986). Recent studies (Maggio et al., 1993) have shown that
functional intermolecular interactions also occur with the
muscarinic and the adrenergic receptors. These receptors,
like the LH/CG receptor, belong to the G-protein-coupled
receptor family. These otherwise independent observations
appear to be consistent with the results described above. It
can therefore be assumed that signal transduction by hCG
takes place by sequential binding of the receptors to two
quasiequivalent sites, leading to receptor dimerization, as in
the case of growth factors.
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